FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2466223643> ?p ?o ?g. }

• W2466223643 abstract "The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin 1 (mTORC1) signaling pathway is aberrantly activated in renal cell carcinoma (RCC). We previously demonstrated glycogen synthase kinase-3β (GSK-3β) positively regulated RCC proliferation. The aim of this study was to evaluate the role of GSK-3 in the PI3K/Akt/mTORC1 pathway and regulation of the downstream substrates, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), ribosomal protein S6 kinase (S6K), and ribosomal protein S6 (S6RP). We used human RCC cell lines (ACHN, Caki1, and A498) and, as normal controls, human renal proximal tubular epithelial cell (HRPTEpC) and non-tumorous kidney tissues that were obtained surgically for treatment of RCC patients. Rapamycin-resistant ACHN (ACHN/RR) cells were generated with chronic exposure of ACHN to rapamycin ranging from 1nM finally to 1 μM. Cell viability, cell cycling and direct interaction between GSK-3β and 4EBP1 were evaluated with MTS assay, flowcytometry and in vitro kinase assay with recombinant GSK-3β and 4EBP1products, respectively. Protein expression and phosphorylation of molecules associated with the PI3K/Akt/mTORC1 pathway were examined by immunoblotting. Effects of drug combination were determined as the combination index with CompuSyn software. Overexpression and phosphorylation of 4EBP1 and S6RP together with GSK-3 activation were observed in RCC cell lines, but not in human normal kidney cells and tissues. Cell proliferation, p4EBP1 and pS6RP were strongly suppressed by GSK-3 inhibition. Rapamycin and LY294002 sufficiently decreased pS6RP, but only moderately p4EBP1. In vitro kinase assays showed that recombinant GSK-3β phosphorylated recombinant 4EBP1, and the effect was blocked by GSK-3 inhibitors. Different from rapamycin, AR- A014418 remarkably inhibited cell proliferation, and rapidly suppressed p4EBP1 and pS6RP in ACHN and ACHN/RR (in 30 min to 1 h). AR- A014418 and rapamycin combination showed additivity at lower concentrations, but antagonism at higher concentrations. GSK-3β could directly phosphorylate 4EBP1 and activate the mTORC1 downstream signaling cascades to enhance protein biosynthesis and cell proliferation in RCC cell lines independent of rapamycin sensitivity. The direct GSK-3β/4EBP1 pathway might be an important subcellular mechanism as an inherent equipment for RCC cells to acquire clinical chemoresistance to mTORC1 inhibitors." @default.
• W2466223643 created "2016-07-22" @default.
• W2466223643 creator A5007596741 @default.
• W2466223643 creator A5010300952 @default.
• W2466223643 creator A5011987568 @default.
• W2466223643 creator A5015451902 @default.
• W2466223643 creator A5023764914 @default.
• W2466223643 creator A5024597836 @default.
• W2466223643 creator A5027892519 @default.
• W2466223643 creator A5055477590 @default.
• W2466223643 date "2016-07-07" @default.
• W2466223643 modified "2023-10-17" @default.
• W2466223643 title "GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition" @default.
• W2466223643 cites W1555974132 @default.
• W2466223643 cites W1965766554 @default.
• W2466223643 cites W1966978996 @default.
• W2466223643 cites W1971357899 @default.
• W2466223643 cites W1972343960 @default.
• W2466223643 cites W1972986619 @default.
• W2466223643 cites W1978714931 @default.
• W2466223643 cites W1980456750 @default.
• W2466223643 cites W1981001162 @default.
• W2466223643 cites W1982958012 @default.
• W2466223643 cites W1997546539 @default.
• W2466223643 cites W1999999605 @default.
• W2466223643 cites W2000324903 @default.
• W2466223643 cites W2007241783 @default.
• W2466223643 cites W2015823415 @default.
• W2466223643 cites W2018553282 @default.
• W2466223643 cites W2033830808 @default.
• W2466223643 cites W2061217601 @default.
• W2466223643 cites W2061253404 @default.
• W2466223643 cites W2067298405 @default.
• W2466223643 cites W2067803871 @default.
• W2466223643 cites W2082067798 @default.
• W2466223643 cites W2083993197 @default.
• W2466223643 cites W2084875329 @default.
• W2466223643 cites W2086338749 @default.
• W2466223643 cites W2088813853 @default.
• W2466223643 cites W2096172976 @default.
• W2466223643 cites W2103562758 @default.
• W2466223643 cites W2117547860 @default.
• W2466223643 cites W2139424276 @default.
• W2466223643 cites W2149363027 @default.
• W2466223643 cites W2150595264 @default.
• W2466223643 cites W2152218089 @default.
• W2466223643 cites W2152829361 @default.
• W2466223643 cites W2154305555 @default.
• W2466223643 cites W2155453789 @default.
• W2466223643 cites W2161182074 @default.
• W2466223643 cites W2166010840 @default.
• W2466223643 cites W2167028219 @default.
• W2466223643 cites W2170208738 @default.
• W2466223643 cites W2312282875 @default.
• W2466223643 doi "https://doi.org/10.1186/s12885-016-2418-7" @default.
• W2466223643 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4936323" @default.
• W2466223643 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27387559" @default.
• W2466223643 hasPublicationYear "2016" @default.
• W2466223643 type Work @default.
• W2466223643 sameAs 2466223643 @default.
• W2466223643 citedByCount "34" @default.
• W2466223643 countsByYear W24662236432017 @default.
• W2466223643 countsByYear W24662236432018 @default.
• W2466223643 countsByYear W24662236432019 @default.
• W2466223643 countsByYear W24662236432020 @default.
• W2466223643 countsByYear W24662236432021 @default.
• W2466223643 countsByYear W24662236432022 @default.
• W2466223643 countsByYear W24662236432023 @default.
• W2466223643 crossrefType "journal-article" @default.
• W2466223643 hasAuthorship W2466223643A5007596741 @default.
• W2466223643 hasAuthorship W2466223643A5010300952 @default.
• W2466223643 hasAuthorship W2466223643A5011987568 @default.
• W2466223643 hasAuthorship W2466223643A5015451902 @default.
• W2466223643 hasAuthorship W2466223643A5023764914 @default.
• W2466223643 hasAuthorship W2466223643A5024597836 @default.
• W2466223643 hasAuthorship W2466223643A5027892519 @default.
• W2466223643 hasAuthorship W2466223643A5055477590 @default.
• W2466223643 hasBestOaLocation W24662236431 @default.
• W2466223643 hasConcept C104202773 @default.
• W2466223643 hasConcept C153911025 @default.
• W2466223643 hasConcept C184235292 @default.
• W2466223643 hasConcept C185592680 @default.
• W2466223643 hasConcept C2780926556 @default.
• W2466223643 hasConcept C502942594 @default.
• W2466223643 hasConcept C54355233 @default.
• W2466223643 hasConcept C55493867 @default.
• W2466223643 hasConcept C62112901 @default.
• W2466223643 hasConcept C62478195 @default.
• W2466223643 hasConcept C75217442 @default.
• W2466223643 hasConcept C81885089 @default.
• W2466223643 hasConcept C86554907 @default.
• W2466223643 hasConcept C86803240 @default.
• W2466223643 hasConcept C95444343 @default.
• W2466223643 hasConcept C98490376 @default.
• W2466223643 hasConceptScore W2466223643C104202773 @default.
• W2466223643 hasConceptScore W2466223643C153911025 @default.
• W2466223643 hasConceptScore W2466223643C184235292 @default.
• W2466223643 hasConceptScore W2466223643C185592680 @default.
• W2466223643 hasConceptScore W2466223643C2780926556 @default.
• W2466223643 hasConceptScore W2466223643C502942594 @default.

• next